Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

Articles Tagged With:

  • Business Developments

    Continuing its growth beyond its core arena of interventional cardiology, Boston Scientific (Natick, Massachusetts) early this month said it would buy neurostimulation specialist Advanced Bionics (Valencia, California), through the purchase of 100% of its stock for $740 million in cash, plus future milestone payments.
  • Agreements

    Endocardial Solutions(ESI; St. Paul, Minnesota) reached an agreement with the Mayo Foundation for Medical Education and Research (Rochester, Minnesota) for the development and license of an automated 3-D cardiac segmentation and modeling software product.
  • Product Pipeline

    CryoCath Technologies (Montreal, Quebec) received 510(k) regulatory clearance from the FDA in May for FrostByte, a clamp ablation device to be used in the treatment of cardiac arrhythmias. The company said it expected to receive CE mark approval shortly and launch the product this month.
  • Sub-study findings could have CMS policy implications

    SAN FRANCISCO, California Electrocardiogram (ECG) parameters and QRS durations (ventricular activity shown in an electrocardiogram) are not specific enough to either include or exclude patients to receive implantable cardioverter defibrillator (ICD) therapy, according to a new sub-study analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) presented at the Heart Rhythm Societys (HRS; Natick, Massachusetts) 25th annual scientific sessions.
  • NEJM publishes data from two significant heart failure trials

    Data from two significant heart failure trials COMPANION and DEFINITE was published in the May 20 issue of the New England Journal of Medicine (NEJM), and both trials also were the subject of presentations at the Heart Rhythm Societys (formerly the North American Society for Pacing and Electrophysiology; Natick, Massachusetts) annual scientific sessions, in San Francisco, California.
  • Guidant CEO Dollens reveals plans to retire by the end of the year

    Cardiovasular device powerhouse Guidant (Indianapolis, Indiana) reported on May 18 that Ronald Dollens, the companys president and chief executive officer and a guiding force for the company since its founding, will retire on Dec. 31. The announcement came as a surprise to most industry watchers.
  • Two firms’ cardiac diagnostic tests are cleared for sale by FDA

    Two companies received FDA clearance last month for new cardiac diagnostic tests that could greatly aid in the rapid detection of a potential heart attack, and one in particular could be the wave of the future for emergency room diagnosis of that condition.
  • Market Updates

    The Department of Health and Human Services (HHS) reported last month that it will form a multi-department task force charged with speeding the development of medical technology. The
  • Personnel File

    Grant Wicklund has joined MedCath (Charlotte, North Carolina) as senior vice president and chief administrative officer. Wicklund, who will be responsible for human resources, managed care, materials management/purchasing, administration and MedCaths Cardiology Consulting & Management division, previously was with Tenet Healthcare.
  • Full June 1, 2004 Issue in PDF